Showing results (31-40 of 160) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|December 7, 2017
De-novo and acquired resistance to immune checkpoint targetingNicholas L Syn, Michele W L Teng, Tony S K Mok, et al.
Frontiers in Oncology|April 19, 2014
Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?Sai-Hong Ignatius Ou, Ross A Soo, Akihito Kubo, et al.
Journal of Palliative Medicine|August 18, 2010
Targeted therapy at the end of life for patients with lung cancerAlvin S Wong, Catherine Teo, Siew-Woon Lim, et al.
Therapeutic Advances in Medical Oncology|February 9, 2023
Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutationsJia Li Low, Sun Min Lim, Jii Bum Lee, et al.
Future Oncology (London, England)|September 25, 2024
HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samplesRoss A Soo, Graham Clinthorne, Anu Santhanagopal, et al.
Future Oncology (London, England)|March 9, 2013
Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinomaSun Min Lim, Hye Ryun Kim, Hyo Sup Shim, et al.
Clinical Lung Cancer|April 24, 2017
Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS RegistryRoss A Soo, Akihito Kubo, Masahiko Ando, et al.
Biosensors & Bioelectronics|January 9, 2015
Rapid and label-free amplification and detection assay for genotyping of cancer biomarkerYong Shin, Ross A Soo, Jaeyun Yoon, et al.
Expert Review of Anticancer Therapy|February 8, 2026
Integrating liquid biopsies in non-small cell lung cancer diagnosis and management: opportunities and challengesJeong Uk Lim, Yuko Oya, Rui Fu, et al.
Translational Lung Cancer Research|February 9, 2026
Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic reviewRoss A Soo, Darren Wan-Teck Lim, James Chih-Hsin Yang, et al.
Pageof 16